HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
US10647748B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2018 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Oct 31, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.